A Customer-centric, Innovative
and Reliable CDMO with Global Solutions
About Porton
Porton Pharma Solutions, a global company with R&D, and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercial.
5
Regulated Markets
Approval
4300+
Global
Employees
1200+
R&D
Scientists
2000+
Total
Capacity (m³)
1000+
Global
Customers
3500+
Milestone
Projects
Corporate Culture
Mission & Vision
Enabling the public's early access to good medicines.
Vision
To be the most open, innovative and reliable pharmaceutical service platform in the world.
Our Journey To Excellence
Started CMO2005-2008
Became a Public Company2009-2016
Transformed to a Global Leading CDMO2017 to date
Started CMO2005-2008
2005s
2005
Porton Founded
2006
Started CMO (Changshou) With R&D (Chongqing & Chengdu)
2008
Established Porton USA & Europe(Sales), Shanghai (R&D)
Became a Public Company2009-2016
2009s
2013
1st USFDA Inspection With Zero 483
2014
Listed On Shenzhen StockExchange
Transformed to a Global Leading CDMO2017 to date
2017s
2017
Acquired J-Star Research Inc. (USA)
2020
Passed EMA Inspection, Started DP CDMO Services
2021
Acquired Hubei Plant (China)
2022
Started DP Commercial Plant Operation; Acquired Fengxian (Shanghai) GMP Plant
2023
Started Shanghai Headquarters, DP Facility in USA, DS Facility in EU (Slovenia), Tides and Conjugates Facility in Shanghai
2024
Slovenia Site R&D Facility Operation; Changshou Site Passed USFDA Inspection with Zero 483
